New combination for AML in people who can't have intensive chemo
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two drugs—venetoclax and azacitidine—for people with acute myeloid leukemia (AML) who can't have standard intensive chemo. The goal is to see if adding a boosting medicine (cobicistat) makes the treatment work better and is safe for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a diagnosis of acute myeloid leukemia (AML) or a related early blood cancer (but not a type called acute promyelocytic leukemia).
- You must not be fit for intensive chemotherapy, or you may choose not to have it.
- You should be able to perform daily tasks (WHO performance status 0, 1, or 2).
- Your white blood cell count must be lower than 30 x 10⁹ per liter.
- Your kidney function (creatinine clearance ≥30 mL/min) and liver tests (bilirubin and ALT within 3 times the upper limit of normal) should be in an acceptable range.
- If sexually active, you must agree to use effective birth control during and after treatment (90 days for men, 180 days for women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
This trial tests a new drug (CLN-049) combined with two standard AML medicines (azacitidine and venetoclax) for people who are newly diagnosed with AML and cannot have intensive chemotherapy. It aims to see if this combination is safe and effective for those who are not fit for the usual strong treatment.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial is testing a combination of venetoclax and azacitidine in people with acute myeloid leukemia (AML) who have a high percentage of blast cells (at least 20%) in their bone marrow or blood. It aims to see if this treatment approach can improve outcomes for patients regardless of previous treatments or transplant history.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.